ABT Abbott Laboratories

103.97USD-0.49%Mkt Cap: 179.90B USDP/E: 38.76

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nu…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap179.90B USD
Enterprise Value208.69B USD
Revenue (TTM)48.23B USD
Gross Profit25.01B USD
Net Income (TTM)6.52B USD
Revenue/Share27.73 USD
Last Price103.97 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees122.0K
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)38.76
P/E (Forward)17.50
PEG1.50
EV/EBITDA18.21
EV/Revenue4.33
P/S3.73
P/B3.53
EPS (TTM)2.68 USD
EPS (Forward)5.94 USD
52W Range
81.9744% of range132.03
52W High132.03 USD
52W Low81.97 USD
Profitability
Gross Margin56.42%
Oper. Margin15.65%
EBITDA Margin23.76%
Profit Margin14.72%
ROE12.51%
ROA7.52%
ROIC10.76%
ROCE11.47%
Growth
Revenue Growth14.50%
Earnings Growth-43.60%
Cash Flow & Leverage
Operating CF9.57B USD
CapEx (TTM)2.17B USD
FCF Margin12.58%
FCF Yield3.37%
Net Debt27.14B USD
Net Debt/EBITDA2.37
Net Debt/FCF4.47
Balance Sheet
Debt/Equity0.27
Current Ratio1.46
Quick Ratio0.82
Book Value/Sh29.46 USD
Cash/Share2.48 USD
Dividends
Fwd Div Rate2.52 USD
Trail. Div Rate2.52 USD
Div. Yield2.41%
5Y Avg Yield1.86%
Payout Ratio92.54%
Ex-Div DateOct 15, 2026
Pay DateNov 16, 2026
Splits
Last Split10000:4798
Split DateJan 2, 2013
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)118.91 USD
Upside (mean)+14.4%
Target Range100.00 USD – 130.00 USD
100.00+14.4% to mean130.00
# Analysts26
Ownership
Shares Out.1.73B
Float1.72B
Insiders0.51%
Institutions81.94%
Short Interest
Short Ratio1.9d
Short % Float1.23%
Short % Out.1.10%
Shares Short19.06M
Short (prev mo.)13.63M
Technical
SMA 50103.89 (+0.1%)
SMA 200101.55 (+2.4%)
Beta0.54
S&P 52W Chg12.08%
Avg Vol (30d)8.45M
Avg Vol (10d)8.78M
Technical Indicators
RSI (14)44.0
MACD0.4676
MACD Signal1.2907
MACD Hist.-0.8231
BB Upper114.69 USD
BB Middle107.52 USD
BB Lower100.35 USD
BB Width13.33%
ATR (14)2.921 USD
Vol Ratio (20d)0.76x

About Abbott Laboratories (NYSE: ABT)

›

Abbott Laboratories (NYSE: ABT) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 122,000 employees.

The shares were at 103.97 USD on 19 November 2026, down 15.8% over 52 weeks. Its 52-week range is 81.97 USD to 132.03 USD: the price is 21.3% below the high and 26.8% above the low.

At a market capitalisation of 179.90B USD, it trades at 38.8 times trailing earnings and 17.5 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.4, a premium of 52% for ABT. It pays a dividend yielding 2.41% (it pays out 93% of its earnings), against a median of 2.31% among the dividend payers in that peer group.

Abbott Laboratories reports return on equity of 12.5%, an operating margin of 15.6% and revenue up 14.5% year over year.

Its debt exceeds its cash by 27.14B USD, a debt-to-equity ratio of 0.27. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 26 analysts cover the stock, with an average rating of Buy; their mean price target of 118.91 USD is 14.4% above the current price. The next earnings report is expected on 28 January 2027.